| Date | Title | | | | 11/14/2013 | PCR from Whole Blood, Simplified| CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2013--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide
release of the MyTaqTM Blood-PCR Kit, developed for fast,
highly-specific PCR direct from whole blood samples.
Based on the proven MyTaqTM HS DNA polymerase, in combination
with a novel, red-colored, buffer system; the new Bioline MyTaqTM
Blood-PCR Kit overcomes the ... |
| |  | | 11/7/2013 | Meridian Bioscience Reports Record Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, Announces Increased Regular Cash Dividend Rate for Fiscal 2014, and Reaffirms Fiscal 2014 Guidance| CINCINNATI--(BUSINESS WIRE)--Nov. 7, 2013--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record fourth quarter and full-year fiscal 2013 net sales of
$49.0 million and $188.7 million, respectively, increases of 13% and
9%, respectively, from the same periods of the prior fiscal year;
reported record f... |
| | | | 10/31/2013 | Meridian Life Science Awarded SBIR by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine| MEMPHIS, Tenn.--(BUSINESS WIRE)--Oct. 31, 2013--
Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned
subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), has been selected
by the Centers for Disease Control and Prevention (CDC) to develop a
process for manufacture of a rotavirus vaccine. Funding for this
activity will be provided through a Small Business Innovation Research
(SBIR) contract. Process development will focus on optimiz... |
| | | | 9/9/2013 | Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2014 and Reaffirms Fiscal 2013 Guidance| CINCINNATI--(BUSINESS WIRE)--Sep. 9, 2013--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
provided the financial community with guidance regarding the Company’s
fiscal 2014 sales and earnings estimates. Based on the Company’s
business planning and budgeting activities for the fiscal year ending
September 30, 2014, management expects net sales to be in the range of
$203 to $208 million and per share diluted earnings to be between $0.98
... |
| | | | 7/25/2013 | Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance| CINCINNATI--(BUSINESS WIRE)--Jul. 25, 2013--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported fiscal 2013 third quarter and nine months net sales of $47.1
million and $139.7 million, respectively, increases of 12% and 8%,
respectively, from the same periods of the prior fiscal year;
reported third quarter o... |
| | | | 7/2/2013 | Bioline Launches the MyTaq™ Extract-PCR Kit, Single Tube Extraction of PCR-Ready DNA from Mammalian Tissues| CINCINNATI--(BUSINESS WIRE)--Jul. 2, 2013--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide
release of the MyTaqTM Extract-PCR Kit.
Powered by the high performance MyTaqTM DNA Polymerase, the
MyTaqTM Extract-PCR Kit offers a quick and easy alternative
for the extraction and amplification of DNA from a variety of mammalian
tissue types. Researchers using the ... |
| | | | 6/10/2013 | Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Mycoplasma| CINCINNATI--(BUSINESS WIRE)--Jun. 10, 2013--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced that it has received FDA clearance for a new molecular
diagnostic test for Mycoplasma pneumonia (M. pneumoniae), its
fourth assay on the illumigene platform. This innovative
test that aids in identifying an important respiratory pathogen is a
strong addition to the illumigene platform.
Often referred to as “walking pneumo... |
| | | | 4/25/2013 | Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance| CINCINNATI--(BUSINESS WIRE)--Apr. 25, 2013--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported fiscal 2013 second quarter and six months net sales of $47.3
million and $92.6 million, respectively, flat and an increase of 6%,
respectively, from the same periods of the prior fiscal year;
reported second quar... |
| | | | 3/28/2013 | Meridian Bioscience Recognized by Forbes as One of America’s 100 Most Trustworthy Companies| CINCINNATI--(BUSINESS WIRE)--Mar. 28, 2013--
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has
been recognized by Forbes as one of America’s 100 Most Trustworthy
Companies. The list is selected following a comprehensive evaluation of
governance and accounting practices of candidate companies having market
capitalization over $250 million. The rankings are based on data from
GMI Ratings (GMI) that looks at over 60 governance and account... |
| | | | 3/18/2013 | Meridian Bioscience Announces illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests Categorized “Moderate Complexity” by FDA| CINCINNATI--(BUSINESS WIRE)--Mar. 18, 2013--
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today
announced the U.S. Food & Drug Administration (FDA) has re-categorized
Meridian’s illumigene® Group A Streptococcus
and illumigene® Group B Streptococcus
tests as “Moderate Complexity” under the Clinical Laboratory
Improvement Amendments (CLIA). Moderately complex tests are assays that
are considered to be simple and easy to use.
... |
| | | | 2/6/2013 | Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation| CINCINNATI--(BUSINESS WIRE)--Feb. 6, 2013--
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian
Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide
release of the high performance ISOLATE II range of nucleic acid
purification kits.
Based on filter membrane spin column technology with simple
bind-wash-elute steps; the new Bioline ISOLATE II kits are designed for
fast and efficient isolation of DNA or RNA from ... |
| | | | 1/23/2013 | Meridian Bioscience Reports First Quarter 2013 Operating Results and Reaffirms Fiscal 2013 Guidance| CINCINNATI--(BUSINESS WIRE)--Jan. 23, 2013--
Meridian Bioscience, Inc. (NASDAQ: VIVO):
GENERAL HIGHLIGHTS
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:
reported record first quarter net sales of $45.4 million, an increase
of 13%, from the same period of the prior fiscal year;
reported first quarter operating income of $13.1 million, an increase
of 34%, over the same pe... |
| | |
|
